Citius Oncology, Inc. (CTOR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 4, 2026, details material definitive agreements entered into by Citius Oncology, Inc. on May 4 and May 5, 2026. The Company, an emerging growth company focused on oncology, executed a warrant inducement transaction, amended a related-party promissory note, and secured a new senior term loan facility to fund the commercialization of its product, LYMPHIR.
Key Financial Metrics and Capital Structure
- Warrant Inducement Proceeds: Approximately $11.5 million in aggregate gross proceeds from the exercise of existing warrants at a reduced price of $0.90 per share.
- Debt Facility: A new term loan agreement with an aggregate principal amount of up to $25.0 million, structured in three tranches:
- Tranche 1: $10.0 million funded on May 6, 2026.
- Tranche 2: Up to $7.0 million available upon meeting net revenue and liquidity milestones (starting Oct 1, 2026).
- Tranche 3: Up to $8.0 million available upon meeting additional milestones (starting Jan 1, 2027).
- Interest Rate: Loans bear interest at the greater of (Prime Rate + 6.00%) or 12.75% annually.
- Related Party Debt: A promissory note with Citius Pharmaceuticals, Inc. (Parent) in the original principal amount of $3,800,111 was amended to subordinate repayment to the new senior debt and allow voluntary conversion at $0.90 per share.
- Transaction Fees:
- Warrant Inducement: 7.0% cash fee to placement agent plus up to $85,000 in reimbursable expenses.
- Loan Facility: 6.0% cash fee on committed debt, $250,000 commitment fee, and a final payment of $1,062,500.
Material Changes and Agreements
The filing reports significant changes to the Company's capital structure and debt obligations:
- Warrant Inducement: Existing warrants (12,777,778 shares) were induced to exercise at $0.90 (down from $1.09). In exchange, the Company issued 25,555,556 new warrants with an exercise price of $0.90. Additionally, 15,697,024 shares of "December Warrants" were amended to reduce the exercise price to $0.90 and align expiration with stockholder approval.
- Debt Subordination: All indebtedness to the Parent company (Subordinated Debt) is now subordinated to the new senior loan facility. The Parent cannot receive payment on the Subordinated Debt until 91 days after the Senior Debt is fully paid.
- Equity Issuance: The transaction involves the issuance of unregistered securities (New Warrants, Placement Agent Warrants, Lender Warrants) subject to stockholder approval for the issuance of underlying shares.
Outlook, Risks, and Management Commentary
Use of Proceeds: Net proceeds from the warrant inducement and loan facility are intended to fund ongoing LYMPHIR commercialization efforts, including sales force expansion, market access, medical affairs, and manufacturing supply chain support, with the remainder for working capital.
Risks and Contingencies:
- Stockholder Approval: The New Warrants and Lender Warrants are exercisable only upon stockholder approval, which the Company must seek within 90 days of closing and every 90 days thereafter until obtained.
- Beneficial Ownership Limitations: Exercise of warrants is subject to beneficial ownership limitations (generally 4.99% or 9.99% at election), which may restrict the holder's ability to exercise the full amount immediately.
- Debt Covenants: The Loan Agreement includes customary covenants limiting additional indebtedness, liens, and asset sales. Events of default include non-payment, insolvency, and material adverse effects.
- Prepayment Penalties: Prepayment of the loan incurs fees ranging from 1.0% to 3.0% depending on the timing relative to the closing date.
Key Facts for Investor Verification
- Verify the status of the required stockholder approval for the issuance of shares underlying the New Warrants and Lender Warrants.
- Confirm the specific net revenue and liquidity milestones required to access Tranche 2 and Tranche 3 of the $25.0 million loan facility.
- Review the dilution impact of the 25,555,556 New Warrants, 894,444 Placement Agent Warrants, and the Lender Warrants (calculated based on funded tranches).
- Assess the Company's ability to service the new debt, given the interest-only period and the high interest rate floor of 12.75%.
- Monitor the subordination of the $3.8 million related-party note and its potential conversion into equity at $0.90 per share.